全文获取类型
收费全文 | 895篇 |
免费 | 49篇 |
国内免费 | 20篇 |
专业分类
耳鼻咽喉 | 10篇 |
儿科学 | 36篇 |
妇产科学 | 13篇 |
基础医学 | 80篇 |
口腔科学 | 14篇 |
临床医学 | 92篇 |
内科学 | 178篇 |
皮肤病学 | 21篇 |
神经病学 | 53篇 |
特种医学 | 199篇 |
外科学 | 103篇 |
综合类 | 14篇 |
预防医学 | 60篇 |
眼科学 | 7篇 |
药学 | 54篇 |
2篇 | |
肿瘤学 | 28篇 |
出版年
2021年 | 8篇 |
2020年 | 4篇 |
2019年 | 10篇 |
2018年 | 21篇 |
2017年 | 10篇 |
2016年 | 7篇 |
2015年 | 14篇 |
2014年 | 24篇 |
2013年 | 29篇 |
2012年 | 39篇 |
2011年 | 27篇 |
2010年 | 24篇 |
2009年 | 25篇 |
2008年 | 35篇 |
2007年 | 47篇 |
2006年 | 31篇 |
2005年 | 22篇 |
2004年 | 28篇 |
2003年 | 18篇 |
2002年 | 27篇 |
2001年 | 16篇 |
2000年 | 18篇 |
1999年 | 18篇 |
1998年 | 32篇 |
1997年 | 27篇 |
1996年 | 32篇 |
1995年 | 23篇 |
1994年 | 23篇 |
1993年 | 28篇 |
1992年 | 11篇 |
1991年 | 9篇 |
1990年 | 9篇 |
1989年 | 37篇 |
1988年 | 21篇 |
1987年 | 32篇 |
1986年 | 17篇 |
1985年 | 33篇 |
1984年 | 17篇 |
1983年 | 13篇 |
1982年 | 8篇 |
1981年 | 14篇 |
1980年 | 13篇 |
1979年 | 11篇 |
1978年 | 4篇 |
1977年 | 15篇 |
1976年 | 8篇 |
1975年 | 3篇 |
1973年 | 4篇 |
1972年 | 3篇 |
1971年 | 4篇 |
排序方式: 共有964条查询结果,搜索用时 0 毫秒
961.
Comparative effects of doxazosin and hydrochlorothiazide on serum lipids and blood pressure in essential hypertension 总被引:1,自引:0,他引:1
B N Trost P Weidmann W Riesen J Claessens Y Streulens F Nelemans 《The American journal of cardiology》1987,59(14):99G-104G
The efficacy and safety of doxazosin (mean dosage 6.9 mg, range 1 to 16) in the treatment of essential hypertension were compared in a double-blind study with those of hydrochlorothiazide (HCTZ) (mean dosage, 84.6 mg, range 25 to 100) in 104 hypertensive patients treated once daily for 6 months. Thirty-five patients were also assessed for comparative effects of the 2 agents on serum lipid parameters. Doxazosin produced potentially favorable changes from baseline in the concentrations of serum lipid fractions (total triglycerides, total cholesterol, high density lipoprotein [HDL] cholesterol and the derived HDL/total cholesterol ratio) compared with HCTZ. The decreases in total triglyceride and total cholesterol concentrations and an increase in the HDL/total cholesterol ratio were significantly different (p less than 0.006) from the opposite changes observed with HCTZ. Clinically relevant decreases from baseline in supine and standing blood pressures at 24 hours after administration did not significantly differ between the 2 agents. The incidence and severity of side effects were similar for both drugs. Three patients receiving doxazosin and 6 receiving HCTZ were withdrawn due to drug-related clinical side effects including 2 patients receiving HCTZ who were withdrawn because of laboratory test abnormalities. Eight HCTZ- and 1 doxazosin-treated patients developed hypokalemia and 6 HCTZ-treated patients developed hyperuricemia. These findings indicate that doxazosin and HCTZ provide comparable antihypertensive efficacy after 6 months of treatment using a once-daily regimen, but doxazosin produces a beneficial effect on the serum lipid profile as well as fewer biochemical aberrations. 相似文献
962.
Jane Watts Georgia Alexandra Box Angela Galvin Frans Van Tonder Nicholas Trost Thomas Sutherland 《Journal of Medical Imaging and Radiation Oncology》2014,58(5):569-581
Magnetic resonance imaging (MRI) is the modality of choice for the investigation of intramedullary lesions of the spinal cord. A wide variety of conditions may result in similar imaging findings on MRI, and it is essential that the reporting radiologist have a detailed understanding of spinal cord anatomy, the pertinent imaging features of specific intramedullary lesions and the typical clinical presentation of those conditions to aid clinicians to make a prompt diagnosis. This pictorial essay discusses the clinical features and MRI appearance of a number of intramedullary conditions, which can be broadly categorised as congenital, demyelinating, vascular, neoplastic or infectious, and highlights their differentiating features. 相似文献
963.
W. B. Smith II I. R. McCaslin A. Gokce S. H. Mandava L. Trost W. J. Hellstrom 《International journal of clinical practice》2013,67(8):768-780
Introduction: Erectile dysfunction (ED) is a highly prevalent condition affecting nearly one in five men worldwide. The advent of phosphodiesterase type 5 inhibitors (PDE5i) has revolutionised the ED treatment landscape and provided effective, minimally invasive therapies to restore male sexual function. Materials and methods: A pubmed search was performed of all English language articles from 1996 to present reviewing PDE5i, including pharmacokinetics, efficacy profiles and comparisons, where available. Results: Currently available PDE5i in the United States include sildenafil, vardenafil, tadalafil and avanafil, each of which has unique side effect, pharmacokinetic and outcome profiles. Sildenafil is associated with increased rate of visual changes, vardenafil with QT prolongation and tadalafil with lower back pain. Avanafil and vardenafil orodispersible tablet rapidly achieve peak plasma concentration, which results in faster onset of action, whereas tadalafil exhibits the longest half‐life. First time response to PDE5i is approximately 60–70%, with no significant differences in efficacy noted among therapies. The literature does not clearly demonstrate a preference for one drug. High‐treatment success rates (89%) were reported when patients were prescribed all available PDE5i. Daily dosing with tadalafil is associated with improved erectile function (EF) over time. Finally, novel modes of patient–provider interaction, including internet‐based education, communication and prescribing, may also improve long‐term adherence. Conclusions: PDE5i represent first line therapy for ED with excellent overall efficacy and satisfactory side effect profiles. Enhanced communciation, coupled with increased knowledge of drug characteristics, comparative treatment regimens and optimal prescribing patterns, offer compelling tools to improve long‐term treatment success. 相似文献
964.